JP2024516748A5 - - Google Patents

Info

Publication number
JP2024516748A5
JP2024516748A5 JP2024508815A JP2024508815A JP2024516748A5 JP 2024516748 A5 JP2024516748 A5 JP 2024516748A5 JP 2024508815 A JP2024508815 A JP 2024508815A JP 2024508815 A JP2024508815 A JP 2024508815A JP 2024516748 A5 JP2024516748 A5 JP 2024516748A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
cancer
approximately
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516748A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2022/050379 external-priority patent/WO2022226584A1/en
Publication of JP2024516748A publication Critical patent/JP2024516748A/ja
Publication of JP2024516748A5 publication Critical patent/JP2024516748A5/ja
Pending legal-status Critical Current

Links

JP2024508815A 2021-04-26 2022-04-26 ＥＧＦＲｖＩＩＩ結合タンパク質 Pending JP2024516748A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2021901227 2021-04-26
AU2021901226A AU2021901226A0 (en) 2021-04-26 EGFRvIII BINDING PROTEINS II
AU2021901226 2021-04-26
AU2021901227A AU2021901227A0 (en) 2021-04-26 EGFRvIII BINDING PROTEINS I
PCT/AU2022/050379 WO2022226584A1 (en) 2021-04-26 2022-04-26 EGFRvIII BINDING PROTEINS

Publications (2)

Publication Number Publication Date
JP2024516748A JP2024516748A (ja) 2024-04-16
JP2024516748A5 true JP2024516748A5 (cg-RX-API-DMAC7.html) 2025-04-22

Family

ID=83846542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508815A Pending JP2024516748A (ja) 2021-04-26 2022-04-26 ＥＧＦＲｖＩＩＩ結合タンパク質

Country Status (5)

Country Link
US (1) US20240207407A1 (cg-RX-API-DMAC7.html)
EP (1) EP4330285A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024516748A (cg-RX-API-DMAC7.html)
AU (1) AU2022267410A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022226584A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240005794A (ko) * 2021-05-18 2024-01-12 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 항 pd-1 폴리펩티드 및 그의 용도
WO2025080980A1 (en) * 2023-10-13 2025-04-17 The General Hospital Corporation Treating glioblastoma using car-t cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6647868B2 (ja) * 2013-02-20 2020-02-14 ノバルティス アーゲー ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置
AR099812A1 (es) * 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
WO2016016341A1 (en) * 2014-07-29 2016-02-04 Cellectis EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY
WO2020172553A1 (en) * 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
CN113853388B (zh) * 2019-03-27 2024-07-19 加拿大国家研究委员会 抗-egfrviii抗体及其抗原结合片段

Similar Documents

Publication Publication Date Title
JP2021520788A5 (cg-RX-API-DMAC7.html)
JP2022523781A5 (cg-RX-API-DMAC7.html)
IL295604A (en) Methods of making chimeric antigen receptor-expressing cells
JP2021534783A5 (cg-RX-API-DMAC7.html)
RU2017105161A (ru) Лечение рака с использованием химерного антигенного рецептора cll-1
JP2017530694A5 (cg-RX-API-DMAC7.html)
JP7527641B2 (ja) スイッチ分子及びスイッチャブルキメラ抗原受容体
RU2017105160A (ru) Лечение рака с помощью химерного антигенного рецептора к cd33
JP2024539506A5 (cg-RX-API-DMAC7.html)
CA3032581A1 (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
RU2017108903A (ru) Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
JP2017522879A5 (cg-RX-API-DMAC7.html)
JP2019516352A5 (cg-RX-API-DMAC7.html)
JP2017524367A5 (cg-RX-API-DMAC7.html)
IL298326A (en) Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
EP4034245A1 (en) Trivalent binding molecules
KR20230042753A (ko) Egfr을 표적화하는 항체 및 그의 용도
JP2022551757A5 (cg-RX-API-DMAC7.html)
JP2024532482A5 (cg-RX-API-DMAC7.html)
JP2021530233A5 (cg-RX-API-DMAC7.html)
JP2022538425A5 (cg-RX-API-DMAC7.html)
JP2024516748A5 (cg-RX-API-DMAC7.html)
JP2023518930A5 (cg-RX-API-DMAC7.html)
US20250051443A1 (en) Anti-cd3 monoclonal antibodies and therapeutic constructs
JP2023516067A5 (cg-RX-API-DMAC7.html)